Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial.

By H. Nakamura, K. Arakawa, H. Itakura, A. Kitabatake, Y. Gotō, T. Toyota, N. Nakaya, Shoji Nishimoto, M. Muranaka, A. Yamamoto and 2 more. The Lancet, 2006

905 citations recorded by the source corpus.

Subfields: Biotechnology, Cancer Research, Surgery

View Paper: https://www.semanticscholar.org/paper/a8d71e03db3466608237f9d9f603a01448650b7f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. S. Daniels
2. S. Grundy

In Surgery

1. D. Lloyd‐Jones
2. Judith Hochman
3. S. Gidding
4. S. Grundy
5. R. Eckel
6. R. Bilous

Citations in the corpus

• 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, background): “Specific statins and doses are noted in bold that were evaluated in RCTs (17,18,46-48,64-67,69-78) included in CQ1, CQ2 and the CTT 2010 meta-analysis included in CQ3 (20).”
• National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. (2015, methodology): “5% 10-year risk projected from rates observed over shorter observation periods).(74,76,266) The threshold of $10% 10-year risk for a hard CHD event using the ATP III Framingham Risk calculator was selected because it is roughly equivalent to 15% ASCVD risk, assuming the risk for stroke represents ap”
• Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. (2011, background): “This five-year primary prevention trial of hypercholesterolemic Japanese, primarily female, patients found a lower statin dose (pravastatin 10 to 20 mg) combined with diet reduced cardiovascular risk by 25% over diet alone.(34) An individual-level meta-analysis of 14 randomized placebo-controlled tr”
• Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. (2014, background): “Specific statins and doses are noted in bold that were evaluated in RCTs (17,18,46-48,64-67,69-78) included in CQ1, CQ2 and the CTT 2010 meta-analysis included in CQ3 (20).”